BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 13, Issue 11
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review
©The Author(s) 2021.
World J Hepatol. Nov 27, 2021; 13(11): 1552-1567
Published online Nov 27, 2021. doi: 10.4254/wjh.v13.i11.1552
Table 2 Twenty-four hours urine copper and non-ceruloplasmin copper in various stages of Wilson’s disease treatment
Early stages of treatment (< 1 yr)UCu > 500 μg/dNCC > 25 μg/dL
Good control (treatment > 1 yr)UCu 200-500 μg/dNCC < 15 μg/dL
Poor compliance/uncontrolled diseaseUCu > 500 μg/dNCC > 15 μg/dL
Inadequate doseUCu < 200 μg/dNCC > 15 μg/dL
Over-treatmentUCu < 200 μg/dNCC < 5 μg/dL
UCu: Twenty-four hours urinary copper; NCC: Non ceruloplasmin copper.
Full Size Table
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.